PI3K Inhibitors for PIK3CA-Mutated HR+ MBC
Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.
Targeting the PI3K Pathway in HR+/HER2- MBC
The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.
CDK4/6 Treatment Selection for HR+/HER2- MBC
The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.
Comparison of CDK4/6 Therapies for HR+/HER2- MBC
Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.
HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities
Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.
HR+/HER2- MBC: CDK4/6 Inhibitors + ET as Frontline Therapy
Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.
MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy
Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.
Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data
Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.
HR+/HER2- MBC: Updated OS Data From MONALEESA-2
Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.
Frontline Treatment Approaches for HR+/HER2- MBC
A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.
HR+ MBC: Prognostic Factors and Treatment Planning
Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.
Identifying PIK3CA Mutations in HR+ HER2- MBC
Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.
Monitoring Patients for Interstitial Lung Disease
Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.
Identifying Risk Factors for Interstitial Lung Disease
A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.
Identifying ILD: Symptomology and Work-Up
Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.
An Overview of Interstitial Lung Disease
Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.
Multidisciplinary Care in Breast Cancer: Take-Home Messages
Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.
Practical Considerations for Identifying and Managing ILD in Breast Cancer
Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.
Optimal Management of ILD in Patients With Breast Cancer
Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.
Breast Cancer Management: Monitoring Patients for ILD
In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.
Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer
An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.
Challenges in the Multidisciplinary Management of Breast Cancer
Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.
Multidisciplinary Care in BC: How Best to Communicate Patient Information
Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.
Difference in Breast Cancer Outcomes With Multidisciplinary Care
Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.
Managing Breast Cancer: Collaboration Throughout the Treatment Journey
Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.
Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?
Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.
Future Directions for Treatment of TNBC
Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events
Phase 3 ASCENT Trial in mTNBC
Sequencing Therapies for mTNBC
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
2 Clarke Drive Cranbury, NJ 08512